<DOC>
	<DOCNO>NCT01512199</DOCNO>
	<brief_summary>This Phase 1b/2 study . In Phase 1b portion , subject know treatment receiving . Subjects receive U3-1287 trastuzumab plus paclitaxel . The phase 1b portion determine add U3-1287 trastuzumab plus paclitaxel safe subject metastatic breast cancer . In phase 2 portion , subject blind treatment receive . Subjects receive either trastuzumab plus paclitaxel U3-1287 trastuzumab plus paclitaxel placebo.The phase 2 portion determine add U3-1287 trastuzumab plus paclitaxel safe improve survival subject metastatic breast cancer .</brief_summary>
	<brief_title>Phase 1b/2 Study U3-1287 Combination With Trastuzumab Plus Paclitaxel Newly Diagnosed Metastatic Breast Cancer ( MBC )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subjects must satisfy follow criterion include study : 1 . Women ≥ 18 year old . 2 . Histologically cytologically confirm adenocarcinoma breast metastatic disease least 1 measurable lesion per Response Evaluation Criteria Solid Tumors ( RECIST ) guideline Version 1.1 . 3 . Documented HER2+ disease measure FISH IHC ( 3+ ) . See Appendix 17.8 documentation criterion . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 5 . Hematological function , follow : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L Platelet count &gt; 100 x 109/L Hemoglobin ≥9 g/dL . 6 . Renal function , follow : Calculated creatinine clearance ≥60 mL/min use modify Cockcroft Gault equation . 7 . Hepatic function , follow : AST ≤2.5 x ULN ( liver metastasis present , &lt; 5 x ULN ) ALT ≤2.5 x ULN ( liver metastasis present , &lt; 5 x ULN ) Alkaline phosphatase ≤ 2.0 x ULN ( bone liver metastases present , &lt; 5 x ULN ) Bilirubin ≤1.5 x ULN . 8 . Prothrombin time ( PT ) partial thromboplastin time ( PTT ) ≤1.5 x ULN . 9 . Availability archive tumor sample fresh tumor specimen ( provide treatment start ) confirm HER2 status tumor biomarkers/mutation analysis . 10 . Subjects must postmenopausal ( menstrual period minimum 12 month ) surgically sterile , must use maximally effective birth control period therapy , willing use contraception 6 month follow last investigational drug dose negative urine serum pregnancy test upon entry study subject childbearing potential . Partners subject must surgically sterile willing use double barrier contraception method upon enrollment , course study , 6 month last investigational drug dose receive . 11 . Subjects must willing able comply schedule visit , treatment plan , laboratory test , study procedure . 12 . Subjects must competent able comprehend , sign , date IEC IRBapproved ICF performance study specific procedure test . Subjects meet follow criterion disqualify enter study : 1 . Prior treatment metastatic disease radiation therapy . Neoadjuvant/adjuvant therapy paclitaxel , and/or docetaxel , and/or trastuzumab allow complete 12 month prior relapse/progression . 2 . Clinically active brain metastasis , define untreated symptomatic , require therapy steroid anticonvulsant control associate symptom . Subjects treat brain metastasis longer symptomatic require treatment steroid anticonvulsant may include study recover acute toxic effect radiotherapy . 3 . LVEF &lt; 50 % . History LVEF decline &lt; 50 % prior trastuzumab therapy . 4 . Therapeutic palliative radiation therapy major surgery within 4 week study drug treatment . 5 . History malignancy , except adequately treat nonmelanoma skin cancer , curatively treated situ cancer , solid tumor curatively treat evidence disease ≥ 5 year . 6 . Uncontrolled hypertension ( diastolic blood pressure &gt; 100 mmHg systolic blood pressure &gt; 140 mmHg ) . Use antihypertensive medication permissible maintain blood pressure within required parameter . 7 . Clinically significant electrocardiogram ( ECG ) change obscure ability ass RR , PR , QT , QTc QRS interval . 8 . Subjects leave bundle branch block , atrial fibrillation use cardiac pacemaker specifically exclude . 9 . Ascites pleural effusion require chronic medical intervention . 10 . Preexisting peripheral neuropathy &gt; grade 1 . 11 . Myocardial infarction , symptomatic CHF ( New York Heart Association &gt; Class II ) , unstable angina , unstable cardiac arrhythmia require medication within 1 year enrollment . 12 . Use cytochrome P450 ( CYP ) 3A4 ( CYP3A4 ) CYP2C8 inducer within 28 day prior Day 1 , use CYP3A4 CYP2C8 inhibitor within 14 day prior Day 1 , concurrent use CYP3A4 CYP2C8 inducer inhibitor ( see Appendix 17.6 list CYP34A CYP2C8 inhibitor inducer ) . 13 . Use amiodarone within 6 month prior enrollment . 14 . Concurrent use antiarrhythmic medication . 15 . Participated clinical drug study within 4 week ( 2 week small molecule tyrosine kinase inhibitor ; 6 week mitomycin C nitrosoureas ) study drug treatment . Current participation investigational protocol procedure . 16 . Uncontrolled infection require IV antibiotic , antiviral , antifungal . 17 . Known human immunodeficiency virus ( HIV ) infection , active hepatitis B C infection . 18 . History hypersensitivity study drug excipients . 19 . Serious intercurrent medical psychiatric illness condition opinion Investigator would impair ability give inform consent unacceptably reduce protocol compliance safety study treatment . 20 . Pregnant , breastfeeding , unwilling/unable use acceptable contraception . 21 . QTc interval &gt; 450 msec Friderica 's formula two successive screening measurement ( second measurement require first measurement &gt; 450 msec . 22 . Personal family history longQT syndrome . 23 . Subjects receive drug may affect QTc ( eg , quinidine moxifloxacin ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>U3-1287</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>newly diagnose HER-2 positive</keyword>
	<keyword>breast cancer</keyword>
	<keyword>metastatic</keyword>
</DOC>